Inclusion Criteria:

          1. Be willing and able to provide written informed consent for the trial.

          2. Be > or = to 18 years of age on day of signing informed consent.

          3. Have measurable or evaluable disease based on modified RECIST for mesothelioma
             (Byrne, 2004).

          4. Be willing to undergo a video assisted thoracoscopy surgery (VATS) to provide
             diagnostic tissue.

          5. Have a free pleural space to allow for a VATS procedure

          6. Have a performance status of 0 or 1 on the ECOG Performance Scale

          7. Have adequate cardiac function as assessed by echocardiogram, with an EF > 45%

          8. Have adequate pulmonary function to tolerate surgery. Patients must have a diffusing
             lung capacity for carbon monoxide (DLCO) >35% of predicted post-operative FEV1
             (ppoFEV1)

          9. Arterial blood gas predicted postoperative pCO2 < 50

         10. Demonstrate adequate organ function as defined below, all screening labs should be
             performed within 14 days of registration.

             Adequate Organ Function Laboratory Values

             HEMATOLOGICAL Absolute neutrophil count (ANC) ≥ 1,500 /mcL Platelets ≥ 100,000 / mcL
             Hemoglobin ≥ 9 g/dL

             RENAL Serum creatinine ≤ 1.5 X upper limit of normal (ULN) OR Measured or calculated
             creatinine clearance (GFR can also be used in place of creatinine or CrCl) ≥ 60
             mL/min for subject with creatinine levels > 1.5 X institutional ULN

             HEPATIC Serum total bilirubin ≤ 1.5 X ULN AST (SGOT) and ALT (SGPT) ≤ 2.5 X ULN

             COAGULATION International Normalized Ratio (INR) or Prothrombin Time (PT) Activated
             Partial Thromboplastin Time (aPTT) ≤ 1.5 X ULN. Patients on anticoagulation are
             expected to hold anticoagulation for at least 5 days prior to surgery.

             PULMONARY DLCO > 35% of ppoFEV1

             CARDIAC TTE= EF > 45%

         11. Have no extrathoracic disease by best surgical staging.

         12. Female subjects of childbearing potential should have a negative urine or serum
             pregnancy within 72 hours prior to receiving the first dose of study medication. If
             the urine test is positive or cannot be confirmed as negative, a serum pregnancy test
             will be required.

         13. Female subjects of childbearing potential should be willing to use 2 methods of birth
             control or be surgically sterile, or abstain from heterosexual activity for the
             course of the study through 120 days after the last dose of study medication
             (Reference Section 5.8.2). Subjects of childbearing potential are those who have not
             been surgically sterilized or have not been free from menses for > 1 year.

         14. Male subjects should agree to use an adequate method of contraception starting with
             the first dose of study therapy through 120 days after the last dose of study
             therapy.

        Exclusion Criteria:

          1. Is currently participating in a study of an investigational agent and received an
             investigational agent within 4 weeks of the first dose of treatment.

          2. Has received any prior anticancer therapy for mesothelioma (no prior chemotherapy,
             immunotherapy, or targeted therapy).

          3. Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any
             other form of immunosuppressive therapy within 7 days prior to the first dose of
             trial treatment during the neoadjuvant pembrolizumab and optional adjuvant
             pembrolizumab stages.

          4. Has a known history of active TB (Bacillus Tuberculosis)

          5. Hypersensitivity to pembrolizumab or any of its excipients.

          6. Has a known additional malignancy that is progressing or requires active treatment
             within the past 3 years. Exceptions include basal cell carcinoma of the skin or
             squamous cell carcinoma of the skin that has undergone potentially curative therapy
             or in situ cervical cancer or other tumors that will not affect life expectancy.

          7. Has known active central nervous system (CNS) metastases and/or carcinomatous
             meningitis.

          8. Has active autoimmune disease that has required systemic treatment in the past 2
             years (i.e. with use of disease modifying agents, corticosteroids (with higher than
             physiologic doses) or immunosuppressive drugs). Replacement therapy (e.g.: thyroxine,
             insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary
             insufficiency, etc.) is not considered a form of systemic treatment.

          9. Has known history of, or any evidence of active, non-infectious pneumonitis.

         10. Has an active infection requiring systemic therapy.

         11. Has a history or current evidence of any condition, therapy, or laboratory
             abnormality that might confound the results of the trial, interfere with the
             subject's participation for the full duration of the trial, or is not in the best
             interest of the subject to participate, in the opinion of the treating investigator.

         12. Has known psychiatric or substance abuse disorders that would interfere with
             cooperation with the requirements of the trial.

         13. Is pregnant or breastfeeding, or expecting to conceive or father children within the
             projected duration of the trial, starting with the screening visit through 120 days
             after the last dose of trial treatment.

         14. Has a known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies).

         15. Has known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNA
             [qualitative] is detected).

         16. Is on anticoagulation that cannot be discontinued in the perioperative stage.

         17. Has received a live vaccine within 30 days of planned start of study therapy. Note:
             Seasonal influenza vaccines for injection are generally inactivated flu vaccines and
             are allowed; however intranasal influenza vaccines (e.g., Flu-Mist®) are live
             attenuated vaccines, and are not allowed.